Chinese Firms Secure 8 of Global Top 10 Biotech Deals
First-half technology licensing-out deals reach $99.7 billion
Already exceed 70% of last year's full-year total
Value reassessed through platforms and NewCos
An analysis has found that Chinese companies accounted for eight of the world's top 10 biotech deals in the first half of this year. This means multinational pharmaceutical companies are buying most of their major novel drug candidates and technologies from China. Analysts say the prices of Chinese innovative assets are being reassessed by global standards.
According to a monthly report by Deloitte China on October 15, the value of licensing-out deals by Chinese companies in the first half of this year totaled about $99.7 billion (approximately 133.9 trillion won). That is nearly twice the full-year total for 2024 and more than 70% of last year's full-year total. The report noted that, because China's domestic market has limited capacity to pay, securing recognition for innovation's value overseas has become essential.
Multinational pharmaceutical companies are also broadening their investments from individual drug candidates to technology platforms. In January, China's CSPC signed a partnership worth $18.5 billion with AstraZeneca. The deal's value was based primarily on rights to extended-release drug-delivery technology and an artificial intelligence (AI)-based peptide discovery platform. A deal worth about $7 billion (approximately 9.401 trillion won) that Insilico Medicine signed in the first half also involved an AI platform that can be used repeatedly.
There have also been successful exits through the NewCo model, in which Chinese companies transfer assets to newly established companies founded with overseas investors. In March, Gilead agreed to acquire Ouro Medicines, co-founded by Keymed, for up to $2.175 billion. Kailera Therapeutics, co-founded by Hengrui Pharmaceuticals, went public on the Nasdaq in the United States in April. Akeso's HARMONi-6 study was selected for a plenary session at this year's American Society of Clinical Oncology (ASCO) meeting, the first China-originated study to be chosen for the session.
Capital market funding flowed to companies with strong potential to expand overseas. Of the 16 healthcare companies listed on the Hong Kong stock exchange in the first half, 11 listed under Chapter 18A, a special provision that allows loss-making biotech companies to go public. Their business areas include antibody-drug conjugates (ADCs), small interfering RNA (siRNA), synthetic lethality, and surgical robots. There were no listings in digital health or medical services.
There were 451 private-market investment deals in the first half, worth $7.5 billion, up 114% from the same period a year earlier. The total had already surpassed the full-year figure for 2024. Last year's largest single investment round was about 1 billion yuan, but four rounds in the 2 billion yuan range closed in the first half of this year. Investment focused on AI drug development, cell therapies, radiopharmaceuticals, and brain-computer interfaces (BCIs).
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The report forecast that this repricing would not spread evenly across the industry. It said only companies that clear regulatory reviews and clinical trials and succeed in global competition are likely to be rewarded.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.